Topline data were announced from pivotal phase 3 studies evaluating povorcitinib in adults with moderate to severe hidradenitis suppurativa.

Avalo Therapeutics' AVTX-009 is advancing in hidradenitis suppurativa, with Phase 2 data expected in 2026. Stifel initiates ...

A new drug application for povorcitinib is expected to be filed in late 2025 to early 2026 to treat adult patients with ...

A recent review highlights how the Mediterranean diet can reduce inflammation and improve outcomes for chronic skin ...

—The results of a new survey indicate that many patients with hidradenitis suppurativa (HS)—especially Blacks and Hispanics—say that the color of their skin may indeed play a role in how ...

Newly released data from the phase 3 STOP-HS clinical trial program reveal positive results in hidradenitis suppurativa from ...

Benzoyl peroxide is one of the most effective and commonly used acne treatments. You’ll find it in prescription and ...

We are thrilled to welcome Michael to Avalo’s Board of Directors during this pivotal time in our Company’s growth,” said Dr. Garry Neil, CEO of Avalo Therapeutics. “Michael’s extensive experience in ...

HS Often Misdiagnosed – Hidradenitis Suppurativa (HS) affects 1 in 100 people, especially Black women, but is frequently mistaken for other skin conditions. Early Diagnosis is Key – Delayed ...

Treatment for hidradenitis suppurativa (HS) varies depending on the condition’s severity. Early HS can be manageable with medication, while more severe cases may require both medication and surgery.

HC Wainwright reissued their buy rating on shares of InflaRx (NASDAQ:IFRX – Free Report) in a report issued on Friday morning ...

Shares of Incyte sank Monday, making it the biggest decliner in the S&P 500 after the release of its latest clinical trial.